Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473888 | 0.88 | HRH3 (0.37) | KCNA3HRH3 | |
| SCHEMBL10867123 | 0.88 | HRH3 (0.37) | KCNA3HRH3 | |
| SCHEMBL15473856 | 0.88 | HRH3 (0.37) | KCNA3HRH3 | |
| SCHEMBL27104567 | 0.88 | ALOX15 (0.49) | KCNA3SPHK1ALOX15SLC6A5HRH3 | |
| SCHEMBL24906776 | 0.83 | KCNA3 (0.39) | KCNA3SPHK1KDM4EALDH1A1GAA | |
| SCHEMBL15471218 | 0.80 | KDM4E (0.37) | KCNA3SPHK1ALOX15KDM4EALDH1A1 | |
| SCHEMBL14174957 | 0.80 | CARM1 (0.52) | HRH3 | |
| SCHEMBL21430360 | 0.78 | ALOX15 (0.37) | ALOX15KDM4EALDH1A1SLC6A5HRH3 | |
| SCHEMBL18173275 | 0.78 | ALOX15 (0.37) | ALOX15KDM4EALDH1A1SLC6A5HRH3 | |
| SCHEMBL6945949 | 0.78 | GNAI3 (0.50) | SPHK1ALOX15SLC6A5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | claimed |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12508226-B2 | Lipid composition | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12370143-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4328309-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12285525-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-116172975-B | Lipid particle, nucleic acid drug comprising same, and composition for nucleic acid delivery | 富士胶片株式会社 | 2025-03-28 | — | — | CN | disclosed |
| CN-114728016-B | Lipid composition | 富士胶片株式会社 | 2024-10-29 | — | — | CN | disclosed |
| US-20240315970-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-113924128-B | Lipid composition | 富士胶片株式会社 | 2024-09-06 | — | — | CN | disclosed |
| EP-3805198-A1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM Corporation (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085604-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210085604-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2021-03-25 | — | — | US | disclosed |
| CN-112262122-A | Compound or salt thereof, and lipid particle | 富士胶片株式会社 | 2021-01-22 | — | — | CN | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370143-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | KCNA3 4050/4885SPHK1 1166/4885ALOX15 1103/4885 |
| US-12285525-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | KCNA3 4050/4885SPHK1 1166/4885ALOX15 1103/4885 |
| US-20240315970-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | NR1H3, NR1H2, LDLR | KCNA3 4050/4885SPHK1 1166/4885ALOX15 1103/4885 |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | KCNA3 4603/4885SPHK1 1371/4885ALOX15 611/4885 |
| US-20210085604-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | NR1H3, NR1H2, LDLR | KCNA3 4071/4885SPHK1 1171/4885ALOX15 1156/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | KCNA3 1772/4885SPHK1 3613/4885ALOX15 4684/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | KCNA3 1452/4885SPHK1 1973/4885ALOX15 2657/4885 |
| US-12508226-B2 | Lipid composition | APOB, NAF1, SLC27A1 | KCNA3 4143/4885SPHK1 1190/4885ALOX15 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.